New Delhi: With questions being raised on the safety of Molnupiravir – an oral antiviral pill approved for treating Covid-19, Indian health experts have pointed out that the benefits of the drug outweigh the potential risks it may have in the case of high-risk patients.
Developed by US-based drug company Merck, Molnupiravir is approved by the US Food and Drug Administration against Covid-19. It is approved by the UK Medicines and Healthcare Products Regulatory Agency (MHRA) for the treatment of mild-to-moderate Covid-19 in adults with a high risk of progression to severe disease, mainly those with pre-existing (comorbid) conditions.
India has also approved the drug amid rising cases of new Covid variant Omicron in India. An expert panel of the Central Drugs Standard Control Organisation had recently approved the antiviral Molnupiravir for restricted use in emergency situations. The antiviral drug will be manufactured by 13 companies in India.
However, the Indian Council of Medical Research (ICMR) Director-General, Balram Bhargava, said that the Molnupiravir is not included in the national Covid taskforce treatment as it has major safety concerns like teratogenicity, mutagenicity, muscle and bone damage among others.
“More importantly contraception has to be done for three months if this drug is given for male and female as the child born could be problematic with teratogenic influences,” he said at a press briefing.
Medical experts, on the other hand, have pointed out that the benefits of the drug outweigh the potential risks it may have in the case of high-risk patients.
But they say as there are very limited options of medicines to treat Covid patients, hence the new approved medicines should be given a try under strict treatment regime protocols.
“Physicians have to keep in mind their patient profiles while prescribing any drug. If the patient is high-risk that is more than 60 years of age, is obese or having cardiovascular disease, hypertension, and/or has chronic lung or kidney or liver disease, then not treating when the disease is mild or moderate can take extreme turns, putting the patient in risk of hospitalisation and as we have seen at the time of Delta variant, even possible death,” said Dr Deepak Talwar, Senior Consultant, Pulmonology and Sleep Medicine, and Chairman, Metro Respiratory Centre.
“We have to use the available therapy rather than counting its side-effects, that too which are potential, but not known,” he added.
According to Dr Dhruva Chaudhry, Head – Pulmonary and Critical Care Medicine at PGIMS, Rohtak, while giving approval, the US FDA as well as the DCGI have gone through the safety data of the drug. “Only once satisfied, this drug has been approved.”
“Even in the phase 3 clinical trials Molnupiravir demonstrated a significant reduction in the risk of hospitalisation or death with no observed safety concerns when compared to the placebo group,” Chaudhry said.
Molnupiravir inhibits the replication of certain RNA viruses. It is basically to be used in treating Covid-19 infected people of more than 50 years of age and in those with multiple comorbidities. The recommended dose of Molnupiravir 800 mg is twice a day for five days. A patient needs to take 40 capsules containing 200 mg of medication.
Over a dozen pharma companies including Torrent, Cipla, Sun Pharma, Dr Reddy’s, Natco, Mylan, and Hetero are in the process to manufacture the oral pill. Cipla, Sun Pharma, and Dr Reddy’s Laboratories are also expected to release Molnupiravir capsules in the coming weeks.
Loading
';
var cat = "?cat=120172";
//$(".main-rhs2427021").theiaStickySidebar();
var instagram_script=document.createElement('script');
instagram_script.defer="defer";
instagram_script.async="async";
instagram_script.src="https://platform.instagram.com/en_US/embeds.js";
document.head.appendChild(instagram_script);
/*************************************/
/*$(window).scroll(function(){
var last = $('div.listing').filter('div:last');
var lastHeight = last.offset().top ;
if(lastHeight + last.height() < $(document).scrollTop() + $(window).height() && nextload==true){
var circle = "";
var myTimer = "";
var interval = 30;
var angle = 0;
var Inverval = "";
var angle_increment = 6;
$.ajax({
url: "/micros/article-list.php" + cat + nextpath,
async: true,
dataType: "json",
beforeSend: function() {
$('div.listing').append(load);
nextload=false;
//console.log("/micros/article-list.php" + cat + nextpath);
ice = 1;
circle = $('.center-section').find('#green-halo');
myTimer = $('.center-section').find('#myTimer');
angle = 0;
Inverval = setInterval(function (){
$(circle).attr("stroke-dasharray", angle + ", 20000");
//myTimer.innerHTML = parseInt(angle/360*100) + '%';
if (angle >= 360) {
angle = 1;
}
angle += angle_increment;
}.bind(this),interval);
},
success: function(data){
nextload=false;
//console.log("success");
//console.log(data);
$.each(data['rows'], function(key,val){
//console.log("data found");
ice = 2;
if(val['id']!='2427021'){
string = '
function pauseEvent(event) {
var videotype = "zee english video";
gtag('event', 'Pause', { 'event_category': videotype, 'event_label': vlabel});
}
function AdloadEvent(event) {
var videotype = "zee english video";
gtag("event", "kaltura_adloaded", { "event_category": videotype, "event_label": vlabel});
}
function AdProgressEvent(event) {
var videotype = "zee english video";
gtag("event", "kaltura_adprogress", { "event_category": videotype, "event_label": vlabel});
}
function adPausedEvent(event) {
var videotype = "zee english video";
gtag("event", "kaltura_adpaused", { "event_category": videotype, "event_label": vlabel});
}
/* End of Kaltura player function code */
$(document).delegate("div[id^='play']", "click", function(){
//console.log($(this).attr("id"));
//console.log($(this).attr("video-source"));
//console.log($(this).attr("video-code"));
var isyoutube = $(this).attr("video-source");
var vurl = $(this).attr("video-path");
var vid = $(this).attr("id");
$(this).hide();
var pvid = $(this).attr("newsid");
var vx = $(this).attr("id").replace('play-','');
var vC = $(this).attr("video-code");
var playDiv = "video-" + vid + "-" + pvid;
if(isyoutube =='No'){
kalturaPlayerAPIReady(vC, playDiv,pvid);
}else{
onYouTubePlay(vid, vC, playDiv,vx, pvid);
}
});
$(document).delegate("div[id^='ptop']", "click", function(){
var vid = $(this).attr("id").replace('ptop','');
$(this).hide();
var pvid = $(this).attr("newsid");
var vurl = $(this).attr("video-path");
//console.log($(this).attr("id") + "--" + vid);
//console.log($(this).parent().children().find('#play-'+vid).attr("video-source"));
//console.log($(this).parent().children().find('#play-'+vid).attr("video-code"));
var isyoutube = $(this).parent().children().find('#play-'+vid).attr("video-source");
var vC = $(this).parent().children().find('#play-'+vid).attr("video-code");
var playDiv = "mvideo-play-" + vid + "-" + pvid;
if(isyoutube =='No'){
//console.log(jwplayer($(this).attr("id")).getState());
kalturaPlayerAPIReady(vC, playDiv,pvid);
var nxti = 3;
var ci = 1;
var nxti_1 = 6;
var nxti_2 = 9;
var nxti_3 = 12;
if($.autopager==false){
var use_ajax = false;
/*var disqus_shortname="zeehindi";
var disqus_identifier; //made of post id and guid
var disqus_url; //post permalink
function loadDisqus(source, identifier, url, nid) {
if (window.DISQUS) {
//alert("if");
jQuery('
').insertAfter(source);
jQuery('#disqus_thread').insertAfter(source); //append the HTML after the link
//if Disqus exists, call it's reset method with new parameters
DISQUS.reset({
reload: true,
config: function () {
this.page.identifier = identifier;
this.page.url = url;
}
});
}else{
jQuery('
').insertAfter(source);
disqus_identifier = identifier; //set the identifier argument
disqus_url = url; //set the permalink argument
pSUPERFLY.virtualPage(prevLoc,$(this).children().find('.left-block').attr('data-title'));
//console.log("Summary: " + $(this).children().find('.left-block').attr('data-summary'));
//console.log("Keyword: " + $(this).children().find('.left-block').attr('data-keyword'));
//history.pushState('' ,'', prevLoc);
loadshare(prevLoc);
}
return false; // stops the iteration after the first one on screen
}
});
if(lastHeight + last.height() < $(document).scrollTop() + $(window).height()){
//console.log("**get");
url = $(next_selector).attr('href');
x=$(next_selector).attr('id');
//console.log("x:" + x);
//handle.autopager('load');
/*setTimeout(function(){
//twttr.widgets.load();
//loadDisqus(jQuery(this), disqus_identifier, disqus_url);
}, 6000);*/
}
//lastoff = last.offset();
//console.log("**" + lastoff + "**");
});
//$( ".content-area" ).click(function(event) {
// console.log(event.target.nodeName);
//});
/*$( ".comment-button" ).live("click", disqusToggle);
function disqusToggle() {
var id = $(this).attr("id");
$("#disqus_thread1" + id).toggle();
};*/
//$(".main-rhs2427021").theiaStickySidebar();
var prev_content_height = $(content_selector).height();
//$(function() {
var layout = $(content_selector);
var st = 0;
///});
}
}
});
/*}
};*/
})(jQuery);
googletag.pubads().setTargeting('category', ["article","Health","Molnupiravir","ICMR","Central Drugs Standard Control Organisation","FDA","MHRA","COVID Pills","COVID-19","Coronavirus"]);
googletag.pubads().enableLazyLoad({ fetchMarginPercent: 50, renderMarginPercent: 50, mobileScaling: 2.0 });
googletag.pubads().disableInitialLoad();
googletag.pubads().enableAsyncRendering();
googletag.pubads().set('page_url','https://zeenews.india.com/');
googletag.pubads().collapseEmptyDivs();
googletag.enableServices();
// OpenWrap code START here
if(typeof PWT.requestBids === 'function'){
PWT.requestBids(
PWT.generateConfForGPT(googletag.pubads().getSlots()),
function(adUnitsArray) {
PWT.addKeyValuePairsToGPTSlots(adUnitsArray);
PWT.ow_BidsReceived = true;
initAdserver(false);
}
);
}
// No need to handle "else" part as we have A9 wrapper on page
// OpenWrap code END here
var FAILSAFE_TIMEOUT = 1000; // this timeout should be more than OpenWrap and A9 timeout
setTimeout(function() {
initAdserver(true); // calling this function with forced mode set to true so that GPT API is always executed
}, FAILSAFE_TIMEOUT);
});
googletag.cmd.push(function() { googletag.display('div-article-rhs-atf-ad'); });
googletag.cmd.push(function() { googletag.display('div-gpt-ad-1504525832454-0'); });
googletag.cmd.push(function() { googletag.display('div-gpt-ad-1504525832454-2'); });
googletag.cmd.push(function() { googletag.display('div-gpt-ad-1504526235866-6'); });
if(inad1){
googletag.cmd.push(function() { googletag.display('div-gpt-ad-AS-Inarticle-1'); });
}
if(inad2){
googletag.cmd.push(function() { googletag.display('div-gpt-ad-AS-Inarticle-2'); });
}
}
on_load_google_ad(PWT);
function on_load_fb_twitter_widgets(){
(function(d, s, id) {
var js, fjs = d.getElementsByTagName(s)[0];
if (d.getElementById(id)) return;
js = d.createElement(s); js.id = id;
js.src = "//connect.facebook.net/en_US/sdk.js#xfbml=1&version=v2.9";
fjs.parentNode.insertBefore(js, fjs);
}(document, 'script', 'facebook-jssdk'));
Image Source : FREEPIK Representative image There are many reasons why gold trinkets, both new and old, lose their lustre over time. The most common cause of your gold jewellery losing its natural brilliance is known to be regular use. The longer you wear them, the less gloss and glitter they have. That’s not all, […]
Lakshmi Ji : पंचांग के अनुसार आज यानि 28 जनवरी 2022, शुक्रवार को माघ कृष्ण पक्ष की एकादशी तिथि है. शास्त्रों में इस एकादशी तिथि को षटतिला एकादशी भी कहा जाता है. शुक्रवार के दिन एकादशी की तिथि पड़ने के कारण इस दिन भगवान विष्णु के साथ-साथ वैभव की देवी लक्ष्मी जी का आशीर्वाद पाने […]
Ganesha Puja : पंचांग के अनुसार 2 फरवरी 2022, बुधवार को माघ मास की शुक्ल पक्ष को प्रतिपदा तिथि है. चंद्रमा कुंभ राशि में गोचर कर रहा है. जहां पर देव गुरु बृहस्पति पहले से ही विराजमान हैं. गुरु और चंद्र की युति से गजकेसरी योग का निर्माण हो रहा है. ज्योतिष शास्त्र में इस […]
